PET scanning is an emerging technology for the clinical evaluation of many disease processes in man. The vast majority of clinical positron emission tomography (PET) studies are performed using a single tracer, fluorodeoxyglucose. Despite the excellent diagnostic performance of this tracer, it has recognised limitations. New tracers offer the potential to both address these limitations, and to establish new applications for PET. Small animal PET is a logical technique for validating new tracers relevant to human diseases. However, interspecies differences in the handling of chemicals may significantly influence the handling of novel tracers. This requires caution in extrapolating findings in animals to expectations of performance in man. Already there are several examples where biodistribution studies in mice would not have predicted the clinical utility of existing PET tracers. Nevertheless, application of a systematic approach to tracer development is likely to speed transition of new tracers from animals into man.

Author

Rodney J Hicks, Donna Dorow and Peter Roselt

Contact Details

Corresponding address:
Professor Rod Hicks, MBBS (Hons), MD, FRACP,
The Centre for Molecular Imaging,
The Peter MacCallum Cancer Centre,
12 Cathedral Place, East Melbourne VIC 2002,
Australia

Reference

ICIS Cancer Imaging Volume 6 Special Issue A
DOI: 10.1102/1470-7330.2006.9098

Date Posted

31 October 2006

Print PDF

Size

3.43 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	13 seconds
ADSL 512Kb/s (Broadband):	54 seconds
64 Kb/s (ISDN):	7 minutes 19 seconds
33.3 Kb/s (Typical Modem):	14 minutes 4 seconds

Screen PDF

Size

297.01 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	4 seconds
64 Kb/s (ISDN):	37 seconds
33.3 Kb/s (Typical Modem):	1 minute 11 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 66356, London, E14 1GW. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.